Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Best Peptides for Traumatic Brain Injury: Research Comparison

Before selecting a peptide for TBI research, understand how each compound addresses different stages of the secondary injury cascade. This table compares mechanism, evidence base, administration route, and research considerations. BPC-157 VEGF upregulation, ni

This comparison does not assign a generated winner or score.

  • Before selecting a peptide for TBI research, understand how each compound addresses different stages of the secondary injury cascade. This table compares mechanism, evidence base, administration route, and research considerations.
  • BPC-157
  • VEGF upregulation, nitric oxide stabilization, angiogenesis
  • Reduced lesion volume by 34% in rat controlled cortical impact models (6-hour post-injury administration)
  • Subcutaneous or intraperitoneal injection
  • Requires refrigeration; degrades rapidly above 8°C; most effective within first 24 hours post-injury
  • Cerebrolysin
  • BDNF and NGF mimicry, Trk receptor activation, synaptic plasticity
  • Improved cognitive outcomes at 90 days in moderate-to-severe TBI patients (RCT, 21-day infusion protocol)
  • Intravenous or intramuscular injection
  • Pre-mixed pharmaceutical solution; daily administration required; evidence strongest for multi-week protocols
  • Dihexa
  • HGF/c-Met pathway activation, dendritic spine formation, synaptogenesis
  • Increased hippocampal spine density by 40% and improved spatial learning by 50% in rodent stroke models
  • Oral or subcutaneous
  • Oral bioavailability 50–60%; supports long-term administration; mechanism targets structural reorganization rather than acute neuroprotection